Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Sensei Biotherapeutics, Inc. (SNSE) provide structured insight into how this clinical stage biotechnology company reports its operations, clinical progress, and corporate actions. Sensei’s common stock is registered on The Nasdaq Stock Market LLC under the symbol SNSE, and the company uses a range of SEC forms to communicate with investors and regulators.
Sensei frequently files Form 8-K to furnish press releases on quarterly financial results and other material events. These filings typically include information on research and development (R&D) and general and administrative (G&A) expenses, cash, cash equivalents and marketable securities, and net loss, along with narrative discussion of clinical milestones. For example, 8-Ks have been used to report financial results for quarters ended March 31, June 30, and September 30, and to attach corresponding press releases as exhibits.
The company also uses Form 8-K to disclose clinical and corporate developments. Filings have furnished press releases on new clinical data for solnerstotug in PD-(L)1 resistant tumors, including presentations at the ESMO Congress, and updates to corporate presentations. Other 8-Ks have described a 1-for-20 reverse stock split intended to help regain compliance with Nasdaq’s minimum bid price requirement and Nasdaq’s subsequent confirmation that Sensei had regained compliance with Listing Rule 5550(a)(2).
A notable 8-K dated October 30, 2025, furnishes a press release announcing that Sensei’s Board of Directors decided to discontinue development of solnerstotug and initiate a strategic review of alternatives, which may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. This filing illustrates how SEC documents capture shifts in corporate strategy and potential changes in the company’s future operations.
On this page, SNSE investors can review Sensei’s SEC filings as they are made available from EDGAR. AI-powered summaries can help explain the key points in lengthy filings, highlight changes in financial condition, and clarify the implications of material events, while the underlying documents remain the authoritative source for detailed information.
James Peyer filed a Form 144 reporting a proposed sale of 950 common shares on
Sensei Biotherapeutics is transforming its business by acquiring Faeth Therapeutics and raising about
After the merger and financing, former Faeth holders and new investors will own the vast majority of Sensei, while existing stockholders drop to about
Donenberg Phillip B. reported acquisition or exercise transactions in a Form 4 filing for SNSE. The filing lists transactions totaling 1,900 shares. Following the reported transactions, holdings were 1,900 shares.
Sensei Biotherapeutics, Inc. director Phillip B. Donenberg filed an initial Form 3 reporting his beneficial ownership of the company’s securities as of February 13, 2026. The filing states that no securities are beneficially owned and lists no derivative positions or transactions.
Sensei Biotherapeutics, Inc. expanded its board of directors from three to five members and appointed Christopher W. Gerry and Phillip B. Donenberg as new directors, effective immediately. Gerry is the Company’s President, Principal Executive Officer and General Counsel, with prior legal and biotech experience. Donenberg brings extensive financial leadership and public company board experience in gene therapy and therapeutics. Donenberg will receive compensation under Sensei’s standard non-employee director program, and both new directors will enter into the Company’s standard form of indemnification agreement.
Sensei Biotherapeutics security holder plans a small stock sale under Rule 144. The notice covers the proposed sale of 1,169 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of
The shares were acquired through restricted stock vesting from the issuer on several dates between 03/09/2023 and 03/09/2025 as compensation. The person filing represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.
Sensei Biotherapeutics, Inc. (SNSE) reported the initial shareholdings of its President and Principal Executive Officer as of 11/14/2025. The executive directly beneficially owns 1,574 shares of common stock, primarily in the form of restricted stock units, with 1,444 shares already vested and 130 shares scheduled to vest in two equal installments on February 15, 2026 and February 15, 2027, subject to continued service.
The executive also holds multiple stock options to purchase common stock with different exercise prices and vesting schedules. These options cover separate grants that generally vest monthly over thirty-six months from their respective commencement dates, with one grant vesting 100% on December 1, 2025, all conditioned on continued service with Sensei Biotherapeutics.
Sensei Biotherapeutics (SNSE) reported Q3 results and outlined major changes to its business. The company posted a net loss of
Sensei discontinued development of its lead program, solnerstotug, and began a review of strategic alternatives, which could include asset sales, licensing, a merger, or an orderly wind-down. To preserve cash, it plans a workforce reduction of approximately 65%, expecting cash charges of about
The company effected a 1‑for‑20 reverse stock split on June 16, 2025. Shares outstanding were 1,261,290 as of November 10, 2025. With R&D at
Sensei Biotherapeutics (SNSE) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025. The disclosure appears under Item 2.02, with the company stating the information "shall not be deemed filed" for purposes of Section 18 of the Exchange Act.
The press release is included as Exhibit 99.1. Sensei’s common stock trades on Nasdaq under the symbol SNSE.
Sensei Biotherapeutics (SNSE) furnished an update under Item 7.01, announcing it has initiated a strategic review to maximize shareholder value. The company disclosed this via a press release titled “Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value,” furnished as Exhibit 99.1. The disclosure is provided under Regulation FD and is not deemed filed under the Exchange Act.